A surrogate cell-based SARS-CoV-2 spike blocking assay

Schuh, Wolfgang; Baus, Lena; Steinmetz, Tobit; Schulz, Sebastian R; Weckwerth, Leonie; Roth, Edith; Hauke, Manuela; Krause, Sara; Morhart, Patrick; Rauh, Manfred; Hoffmann, Markus; Vesper, Niklas; Reth, Michael; Schneider, Holm; Jäck, Hans-Martin; Mielenz, Dirk

To monitor infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and successful vaccination against coronavirus disease 2019 (COVID-19), the kinetics of neutralizing or blocking anti-SARS-CoV-2 antibody titers need to be assessed. Here, we report the development of a quick and inexpensive surrogate SARS-CoV-2 blocking assay (SUBA) using immobilized recombinant human angiotensin-converting enzyme 2 (hACE2) and human cells expressing the native form of surface SARS-CoV-2 spike protein. Spike protein-expressing cells bound to hACE2 in the absence or presence of blocking antibodies were quantified by measuring the optical density of cell-associated crystal violet in a spectrophotometer. The advantages are that SUBA is a fast and inexpensive assay, which does not require biosafety level 2- or 3-approved laboratories. Most importantly, SUBA detects blocking antibodies against the native trimeric cell-bound SARS-CoV-2 spike protein and can be rapidly adjusted to quickly pre-screen already approved therapeutic antibodies or sera from vaccinated individuals for their ACE2 blocking activities against any emerging SARS-CoV-2 variants.